Developing new antibiotics – essential research should not be a question of money
Why has the pharma industry and its talents lost interest in developing new antibiotics?
List view / Grid view
Why has the pharma industry and its talents lost interest in developing new antibiotics?
An NHS-wide plan to use more generic and biologic products has reportedly saved the healthcare provider £700 million since 2016.
This August saw nine new green lights from the FDA, all small molecules, which makes up a third of the approvals this year.
The pharmaceutical company Roche has affirmed that it was hit by a Winnti cyber-attack, thought to be supported by the Chinese government.
Chinese government introduces initiative to enable generic drugs to enter market and reduce prices.
The global biobetters market is set to increase due to demand for higher efficacy and safer drugs.
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028...
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise...
A report conducted by the University of Strathclyde has revealed that the pharmaceutical market in Scotland is booming with over £462m in exports...
NICE has issued a final appraisal determination recommending that venclyxto is made available to patients with chronic lymphocytic leukaemia...
EvaluateMedTech World Preview provides a range of insights into the expected performance of the medtech industry...
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
6 June 2017 | By Niamh Marriott, Junior Editor
The FDA have approved Roche’s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients...
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
5 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma...